Targeting the post-irradiation tumor microenvironment in glioblastoma via inhibition of CXCL12

• Verfasst von: Giordano, Frank Anton [VerfasserIn]
• Verfasst von: Link, Barbara [VerfasserIn]
• Verfasst von: Umansky, Viktor [VerfasserIn]
• Verfasst von: Herskind, Carsten [VerfasserIn]
• Titel: Targeting the post-irradiation tumor microenvironment in glioblastoma via inhibition of CXCL12
• Verf.angabe: Frank A. Giordano, Barbara Link, Martin Glas, Ulrich Herrlinger, Frederik Wenz, Viktor Umansky, J. Martin Brown and Carsten Herskind
• E-Jahr: 2019
• Jahr: 26 February 2019
• Umfang: 17 S.
• Fussnoten: Gesehen am 14.11.2019
• Titel Quelle: Enthalten in: Cancers
• Ort Quelle: Basel : MDPI, 2009
• Jahr Quelle: 2019
• Band/Heft Quelle: 11(2019,3) Artikel-Nummer 272, 17 Seiten
• ISSN Quelle: 2072-6694
• DOI: doi:10.3390/cancers11030272
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: CXCL12
• Sach-SW: glioblastoma
• Sach-SW: radiotherapy
• K10plus-PPN: 1681902869

Abstract

Radiotherapy is a mainstay in glioblastoma therapy as it not only directly targets tumor cells but also depletes the tumor microvasculature. The resulting intra-tumoral hypoxia initiates a chain of events that ultimately leads to re-vascularization, immunosuppression and, ultimately, tumor-regrowth. The key component of this cascade is overexpression of the CXC-motive chemokine ligand 12 (CXCL12), formerly known as stromal-cell derived factor 1 (SDF-1). We here review the role of CXCL12 in recruitment of pro-vasculogenic and immunosuppressive cells and give an overview on future and current drugs that target this axis.